Pharma Follows the PGx Rx | GenomeWeb

Pharma Follows the PGx Rx


Call it the Poste genomic era. Credited with kicking off the pharmacogenomics age with the first genomics database subscription and collaboration — a $125 million deal in 1993 between SmithKline Beecham and Human Genome Sciences — George Poste admits that colleagues thought he was nuts. Since then, pharmas have joined the frenzy, but their efforts could be charitably described as works in progress. Critics say that's a plain sign that pharmacogenomics will never truly get off the ground.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.